Table 2.

Ongoing clinical trials with anti-aging drugs and COVID-19. (from ClinicalTrials.gov)

Intervention / Treatment	Mechanism of action	Clinical Trials
Sirolimus	mTor inhibitor: leads to inhibition of T lymphocyte activation and proliferation; inhibition of antibody production	Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (SCOPE). Age ≥ 18 years Sirolimus in COVID-19 Phase 1 (SirCO-1). Age: 18–65 years old	NCT04341675 NCT04371640
		Sirolimus in COVID-19 Phase 1 (SirCO-1). Age: 18–65 years old	NCT04371640
Hydroxychloroquine, Azithromycin, Sirolimus	Senolytic drug: Hydroxychloroquine alkalinizes the pH in lysosomes, which accumulate in large numbers in senescent cells	Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients (COVID19-HOPE). Age ≥ 18 years	NCT04374903
Quercetin	Anti-inflammatory agent	Effect of Quercetin on Prophylaxis and Treatment of COVID-19. Age ≥ 18 years	NCT04377789
Hydrocortisone	Senolytic drug: SASP inhibition	Hydrocortisone for COVID-19 and Severe Hypoxia (COVID STEROID). Age ≥ 18 years	NCT04348305
Ruxolitinib	Senolytic drug: inhibition of the signalling of cytokines and growth factor receptors that use JAK1 and JAK2 for signalling	Safety and Efficacy of Ruxolitinib for COVID-19. 18–89 years	NCT04348071
		Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS (RuXoCoil). Age ≥ 18 years	NCT04359290
		Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection. 12 years and older	NCT04355793
		Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation (RuxCoFlam). Age ≥ 18 years	NCT04338958
Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin or Tocilizumab	Combination of senolytic drugs; antiviral; and immunomodulation	Randomized Evaluation of COVID-19 Therapy (RECOVERY). All ages	NCT04381936